Myasthenia Gravis

Patients with myasthenia gravis (MG) lived 15 to 19 years longer than those with multiple sclerosis (MS) across 4 datasets.

The phase 3 MINT trial found inebilizumab significantly reduced exacerbations and rescue therapy use in patients with generalized myasthenia gravis.

East Asian patients with generalized myasthenia gravis (gMG) saw meaningful nipocalimab benefits in a Vivacity-MG3 subgroup analysis.

CAR T-cell therapy shows early promise for refractory myasthenia gravis, improving symptoms with mild adverse effects as larger trials loom.

Smartphone remote monitoring captures between-visit symptom changes in myasthenia gravis, spotting week-to-week swings and enabling earlier symptom management than clinic visits.

Interviews with patients living with generalized myasthenia gravis (MG) in the US revealed areas of increased burden in these patients.

A meta-analysis evaluated the efficacy of various monoclonal antibodies in treating patients with myasthenia gravis (MG).

The treatment worked in patients with generalized myasthenia gravis (gMG) regardless of previous immunosuppressive treatment or concomitant use of other gMG treatments.

Efgartigimod has recently been shown effective when investigated to treat ocular myasthenia gravis and juvenile myasthenia gravis.

Tuan Vu, MD, explains the results of the NIMBLE trial, whose results will be presented at the American Academy of Neurology conference.

Both Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scores improved after treatment.

Poor outcomes could be predicted based on the presence of ectopic germinal centers in the thymus in patients with thymoma-associated myasthenia gravis.

The study, evaluating the efficacy of the combination of efgartigimod alfa and hyaluronidase-qvfc, is the first to specifically evaluate those with ocular myasthenia gravis.

The incidence of very late onset of myasthenia gravis has increased in the past 50 years, which has had implications on prognosis.

Increased health care costs, use of nonsteroidal immunosuppressants, and elevated health care costs were associated with use of glucocorticoids by patients with myasthenia gravis.

The efficacy and safety of efgartigimod in pediatric patients will need to be further validated with future studies.

Patients with myasthenia gravis had a more consistent clinical response and fewer deteriorations when using add-on therapy early.